Press releaseGlobe Newswire
Immunocore Holdings
IMCR · NASDAQ
$32.60+$2.76 (+9.25%)TodayMarket closed ·
Prev close $29.84
Latest news
- News
Immunocore Hldgs Q2 2026 Earnings Call Transcript
- Press releaseGlobe Newswire
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
- Press releaseGlobe Newswire
Immunocore reports second quarter financial results and provides a business update
- Press releaseGlobe Newswire
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
- News
Earnings Scheduled For May 6, 2026
- News
Immunocore Hldgs Q1 EPS $0.25 Beats $(0.25) Estimate, Sales $106.677M Miss $107.731M Estimate
- Press releaseGlobe Newswire
Immunocore reports first quarter financial results and provides a business update
- Press releaseGlobe Newswire
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
- Press releasePRNewswire
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
- News
Immunocore Holdings Q4 Earnings Report: What Investors Need to Know
- Press releaseGlobe Newswire
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
- News
Earnings Scheduled For February 25, 2026
- News
Insights into Immunocore Hldgs's Upcoming Earnings
- Press releaseGlobe Newswire
Immunocore announces R&D leadership evolution
- Press releaseGlobe Newswire
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference
- Press releasePRNewswire
Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer
- News
Earnings Scheduled For August 7, 2025
- News
'South Africa, Gates Foundation Pledge Funds to Sustain HIV Research After US Cuts' - Bloomberg News
- News
Demystifying Immunocore Holdings: Insights From 9 Analyst Reviews
- News
Immunocore Hldgs Q1 GAAP EPS $0.10 Beats $(0.39) Estimate, Sales $93.88M Beat $88.52M Estimate
- News
Analyst Expectations For Immunocore Holdings's Future
- NewsAvi Kapoor
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday
- News
What Analysts Are Saying About Immunocore Hldgs Stock
- News
Analyst Expectations For Immunocore Hldgs's Future
- News
Navigating 8 Analyst Ratings For Immunocore Hldgs
- News
A Closer Look at 9 Analyst Recommendations For Immunocore Hldgs
- News
Analyst Ratings For Immunocore Hldgs
- NewsAvi Kapoor
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
- News
Analyst Expectations For Immunocore Hldgs's Future
- News
The Latest Analyst Ratings For Immunocore Hldgs
- News
Deep Dive Into Immunocore Hldgs Stock: Analyst Perspectives (9 Ratings)
- News
Peeling Back The Layers: Exploring Immunocore Hldgs Through Analyst Insights
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.